GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » IVD Medical Holding Ltd (HKSE:01931) » Definitions » EBIT

IVD Medical Holding (HKSE:01931) EBIT : HK$394 Mil (TTM As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is IVD Medical Holding EBIT?

IVD Medical Holding's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2023 was HK$204 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$394 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. IVD Medical Holding's annualized ROC % for the quarter that ended in Dec. 2023 was 11.65%. IVD Medical Holding's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 39.31%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. IVD Medical Holding's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 47.25%.


IVD Medical Holding EBIT Historical Data

The historical data trend for IVD Medical Holding's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IVD Medical Holding EBIT Chart

IVD Medical Holding Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial 339.08 303.12 353.09 351.06 394.16

IVD Medical Holding Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 196.50 135.28 222.19 189.93 204.23

Competitive Comparison of IVD Medical Holding's EBIT

For the Medical Distribution subindustry, IVD Medical Holding's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IVD Medical Holding's EV-to-EBIT Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, IVD Medical Holding's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where IVD Medical Holding's EV-to-EBIT falls into.



IVD Medical Holding EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$394 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


IVD Medical Holding  (HKSE:01931) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

IVD Medical Holding's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

ROC % (Q: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2023 ) + Invested Capital (Q: Dec. 2023 ))/ count )
=478.298 * ( 1 - 24.54% )/( (3089.78 + 3104.419)/ 2 )
=360.9236708/3097.0995
=11.65 %

where

Invested Capital(Q: Jun. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=4980.713 - 525.021 - ( 1365.912 - max(0, 1239.262 - 2984.289+1365.912))
=3089.78

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=5233.789 - 789.725 - ( 1339.645 - max(0, 1311.574 - 3261.882+1339.645))
=3104.419

Note: The Operating Income data used here is two times the semi-annual (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

IVD Medical Holding's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=408.462/( ( (89.076 + max(919.896, 0)) + (100.024 + max(968.902, 0)) )/ 2 )
=408.462/( ( 1008.972 + 1068.926 )/ 2 )
=408.462/1038.949
=39.31 %

where Working Capital is:

Working Capital(Q: Jun. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(537.086 + 899.978 + 158.134) - (525.021 + 0 + 150.281)
=919.896

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(582.063 + 1213.607 + 108.195) - (789.725 + 0 + 145.238)
=968.902

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

IVD Medical Holding's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2023 )
=394.164/834.235
=47.25 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


IVD Medical Holding EBIT Related Terms

Thank you for viewing the detailed overview of IVD Medical Holding's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


IVD Medical Holding (HKSE:01931) Business Description

Traded in Other Exchanges
N/A
Address
Lane 299, Bisheng Road, Room 602, Building 6, Zhangjiang Hi-Tech Park, Pudong New Area District, Shanghai, CHN
IVD Medical Holding Ltd is principally engaged in the sale and manufacture of medical equipment and consumables and the provision of consultancy and maintenance services related to medical equipment. It has three segments. The distribution business, which is the key revenue driver, involves the trading of IVD analysers, reagents, and other consumables to customers such as distributors, hospitals and healthcare institutions, and logistics providers. The After-sales Services provided by Vastec include maintenance and repair services, installation services and end-customer training. Its Self-branded Products Business, distributes its self-developed IVD products under its own brand which includes IVD analysers and reagents under the IVD testing category of Point-of-care testing.
Executives
Leung King Sun
Wu Meizhen 2201 Interest of corporation controlled by you
China International Trust Limited 2201 Interest of corporation controlled by you
Wu Yanfeng 2201 Interest of corporation controlled by you
Wu Mingcong 2201 Interest of corporation controlled by you
Wu Junfeng 2201 Interest of corporation controlled by you
Shen Li 2201 Interest of corporation controlled by you
Nd Medical Technology Limited 2201 Interest of corporation controlled by you
Ma Zhouwei 2201 Interest of corporation controlled by you
Hong Kong Medicine Group Limited 2201 Interest of corporation controlled by you
Hknd Gene Biotechnology Limited 2201 Interest of corporation controlled by you
Fast Benefit Pharmaceutical Limited 2201 Interest of corporation controlled by you
China Smart Pharmaceutical Technology Limited 2201 Interest of corporation controlled by you
3w.com Holding Limited 2201 Interest of corporation controlled by you
Morgan Stanley 2201 Interest of corporation controlled by you

IVD Medical Holding (HKSE:01931) Headlines

No Headlines